SHOCKING: 24 | Mind Blowing Facts

Here's How To Trade This Pattern On BlackBerry, Moderna And Palantir Stocks

BlackBerry Ltd (NYSE: BB), Moderna Inc (NASDAQ: MRNA) and Palantir Technologies Inc (NYSE: PLTR) have been showing strength in

Benzinga · Jul 15, 2022

NOT REAL NEWS: A look at what didn't happen this week

Social media users shared a range of false claims this week

The Independent UK · Jul 15, 2022

COVID-19 vaccines targeting the Omicron variant are on the way — but it could be worth getting a fourth dose now

Omicron is now the dominant strain of COVID-19 around the world and boosters targeting this variant are getting closer to being released.

ABC News · Jul 14, 2022

Experts say there are a number of factors to weigh up about getting a fourth dose of a COVID-19

As millions more people become eligible for a fourth COVID vaccine dose, you might be asking whether you should book in for it or wait for Omicron-specific vaccines still being developed.

ABC News · Jul 9, 2022

Thinking of mixing and matching COVID-19 vaccine booster shots? There doesn't seem to be much point

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

ABC News · Jul 8, 2022

Omicron boosters could be here by fall

As viruses morph and adapt, there's a greater call for targeted vaccines and boosters

Salon · Jul 6, 2022

COVID boosters: When Australians might be able to get their fourth jabs

With a third Omicron wave approaching, the wider Australian population may soon be able to get their second COVID booster shots.

The New Daily · Jul 6, 2022

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga · Jul 5, 2022

COVID vaccines: our current shots could soon be updated to target new variants – an immunology expert explains

More than two years into the pandemic, SARS-CoV-2, the virus that causes COVID-19, continues to challenge us. Its ability to rapidly mutate has seen the evolution of increasingly infectious variants that are getting better at hiding from our immune response.

The Conversation · Jul 5, 2022

Peering Into Moderna's Recent Short Interest

Moderna's (NASDAQ:MRNA) short percent of float has fallen 4.65% since its last report. The company recently reported that it has 14.76 million shares sold short, which is 4.31% of all regular shares that are available for trading.

Benzinga · Jul 5, 2022